HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO
May 20, 2021 07:00 ET
|
Hookipa Pharma Inc
Data from first-in-human Phase 1 study of arenaviral therapeutics, including first data on HB-201/HB-202 alternating 2-vector therapy and expanded data on HB-201, to be featured as oral...
HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights
May 12, 2021 07:00 ET
|
Hookipa Pharma Inc
Oncology programs advance with preliminary Phase 1 immunogenicity data showing robust antigen-specific CD8+ T cell response after one dose of HB-201 or HB-202; clinical results consistent with those...
HOOKIPA Pharma to Report First Quarter 2021 Financial Results on Wednesday, May 12, 2021
May 03, 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, May 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
April 29, 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, April 29, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Present at Kempen Life Science Conference
April 14, 2021 08:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
April 10, 2021 08:31 ET
|
Hookipa Pharma Inc
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202Early data on HB-201 monotherapy show an...
HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook
March 18, 2021 07:00 ET
|
Hookipa Pharma Inc
Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidatesFollow-on offering strengthened cash...
HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021
March 09, 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, March 09, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports Medicine
March 04, 2021 07:00 ET
|
Hookipa Pharma Inc
Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells2-vector approach resulted in tumor cures and...
HOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Global Life Sciences Conference
March 03, 2021 07:00 ET
|
Hookipa Pharma Inc
NEW YORK and VIENNA, Austria, March 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...